NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
NeuroSense Therapeutics Ltd.(NASDAQ: NRSN) (“NeuroSense”), a late-clinical stage biotechnology company developing novel treatments forsevere neurodegenerative diseases, today announced that following a productive discussion with Health Canada (“Agency”), the Company is resuming its regulatory advancement in Canada for PrimeC in amyotrophic lateral sclerosis (ALS). https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg After outlining the remaining requirements, Health Canada confirmed that NeuroSense's proposed […]